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Methods 961 patients referred for PS were referred for PS and electro-
physiological study (EPS). Clinical history, echocardiography and treat-
ment were collected. Patients were followed from 3 months up to 10 years
(5.3±5 years).
Results There were 72 patients ≥60y (mean 68.5±6), 889 patients <60y
(mean 30.5±14). Electrophysiological data and recourse to accessory
pathway (AP) ablation (43% vs. 48.5%, p=0.375) did not significantly differ
between the two groups. Older patients more often had symptomatic forms
(81% vs. 63%, p=0.003) and more often had history of spontaneous atrial
fibrillation (AF)(8% vs. 3%, p=0.01) or poorly-tolerated arrhythmias
(18%vs. 7%, p=0.0009). In multivariable analysis, patients ≥60 had a sig-
nificantly higher risk of history of AF (OR=4.2, 2.1-8.3, p=0.001) and
poorly-tolerated arrhythmias (OR=3.8, 1.8-8.1, p=0.001). In patients who
underwent AP ablation, age ≥60 was associated with an increased risk of
major complication (9.6% vs. 1.9%, p=0.006). During follow-up, occurrence
of AF (13.9% vs. 3.6%, p<0.001) and poorly-tolerated tachycardia (4.2% vs.
0.6%, p=0.001) were more frequent in patients ≥60 although frequency of
ablation failure or recurrence was similar (20% vs. 15.5%, p=0.52). In mul-
tivariable analysis, patients ≥60 had a significantly higher risk of AF
(OR=2.9, 1.2-6.8, p≤0.01).
Conclusions Referring of older patients was infrequent in our clinical prac-
tice (7.5% of patients with a PS). Patients ≥60 have a higher risk of AF and
poorly-tolerated tachycardia both at admission and during follow-up but also
a higher risk of procedure complications. Nevertheless, given a risk of
important complications below 10%, the risk/benefit balance appears to favor
AP ablation in the elderly.
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Introduction Treatment of chronic hepatitis C virus (HCV) infection has
dramatically improved since the advent of direct anti-viral agents, including
Sofosbuvir. Sustained virological response may be achieved in more than 90%
of patients without interferon, ensuring broad use of these regimens. To date,
several thousands of patients have been treated with Sofosbuvir-based regi-
mens worldwide. Since their approval in France, combination therapy is given
to patients with complications, including cirrhosis and life-threatening extra-
hepatic manifestations. 
Methods We analyzed retrospectively the incidence of arrhythmias and
conduction disorder in a cohort of patients treated by Sofosbuvir (new anti-
viral HCV) in our hospital from January 2, 2014 to December 31, 2014. 
Results We observed five cases (1.2%) of severe arrhythmia, including
three cardiac conduction defects, within the first days of Sofosbuvir-based
therapy among 415 patients who had been treated in our center. There
were two females and three males. The median age was 58 (50-75) years.
Two patients were coinfected with HIV. Arrhythmia relapsed when Sofos-
buvir was reintroduced in one patient. Among the 3 conduction disorders,
one patient was under beta-blocker and amiodarone another. A pacemaker
was implanted in all 3 patients with conduction disorders. The three
patients who underwent a pacemaker implantation were not pacemaker-
dependent, on the controls after stopping antiviral treatments (figure 1). 
Conclusion Sofosbuvir seems to have cardiac toxicity. The mechanism
underlying Sofosbuvir cardiotoxicity has to be determined. A particular
attention should be given to patients with a medical history of rhythm
or  conduction abnormalities, including careful monitoring (e.g., Holter
ECG recordings) of cardiac rhythm during the first days of Sofosbuvir
therapy.
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Background Preexcitation syndrome (PS) is a potential cause of sudden
cardiac death; its prognostic assessment is a major issue. The aim was to
assess the contribution of esophageal electrophysiological study (EPS) com-
pared to intracardiac EPS for the prognostic evaluation in patients with PS.
Methods We conducted a prospective single-centre study between
November 1st, 2008 and December 1st, 2014, in patients who underwent both
esophageal and intracardiac EPS for a PS. Accessory pathway effective refrac-
tory period (APERP) and induction of sustained supraventricular tachyarrhyth-
mias (SVT) were noted for both methods.
Results 69 patients were included. 45 (65%) were males and mean age was
36±16 years. There were no significant differences in the induction of SVT
between both methods. APERPs were significantly shorter at esophageal EPS
compared to intracardiac EPS in control state (>40 ms) in 51% of patients, but
APERPs did not decrease significantly after isoproterenol: in these patients
with shorter APERP at esophageal EPS, age and gender was similar to other
patients; APERPs in basal state were shorter than in patients with similar
APERPs at both studies (255±43 vs 281±61)(p0.032), but APERPs after iso-
proterenol were similar (226±33 vs 231±45)(0.55); the shortening of APERP
after infusion of isoproterenol was significantly less than in patients with sim-
ilar APERPs at esophageal and intracardiac EPS (30±31ms vs 49±45
ms)(p<0.05). The sensitivity of esophageal EPS in prognostic assessment was
88% in control state, 100% during isoproterenol infusion. The area under
ROC curve of transesophageal EPS in prognostic assessment based on APERP
measurement was 0.74.
Conclusion Esophageal EPS was a reliable and sensitive method of prog-
nostic assessment in patients with PS. APERP was shorter in 51% of patients
but did not decrease significantly after isoproterenol at esophageal EPS
compared to intracardiac EPS, indicating esophageal EPS-related stress.
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Abstract 0428 – Figure: ECG before, during and after treatment in one case
